TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”)(TOKYO:4565) confirms that Novartis Pharma K.K. launched once-daily Ultibro® Inhalation Capsules (“Ultibro®”; glycopyrronium / indacaterol), for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® was developed by Novartis under the name of QVA149.
Help employers find you! Check out all the jobs and post your resume.
